He also serves as a member of the board of directors of BioMarin Pharmaceutical, Inc., a biopharmaceutical company specializing in rare genetic diseases, since June 2007. In addition, he has served as an advisor to Convergent Ventures (formerly Phoenix Venture Partners), a venture capital firm, since October 2015. Dr. Lawlis previously served as a director of Sutro Biopharma, Inc., a biologics platform company specializing in therapeutics for cancer and autoimmune disorders, from January 2004 to June 2019, Coherus BioSciences, Inc., a biologics platform company specializing in biosimilars, from May 2014 to May 2021, and Aeglea BioTherapeutics, Inc., a biotechnology company specializing in human enzyme therapeutics for rare genetic diseases and cancer, from July 2018 to June 2022. Dr. Lawlis was the President and Chief Executive Officer of Itero Biopharmaceuticals LLC, a privately held, early-stage biopharmaceutical company that he co-founded, from 2006 to 2011.
Dr. Lawlis also held several senior management positions in the biopharmaceutical industry, including President and Chief Executive Officer of Aradigm Corporation, a specialty drug company focused on drug delivery technologies, and President and Chief Executive Officer of Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, which he co-founded. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin and a Ph.D. in biochemistry from Washington State University.
What is V. Bryan Lawlis' net worth?
The estimated net worth of V. Bryan Lawlis is at least $36,766.50 as of April 3rd, 2023. Dr. Lawlis owns 28,950 shares of Geron stock worth more than $36,767 as of April 20th. This net worth estimate does not reflect any other assets that Dr. Lawlis may own. Learn More about V. Bryan Lawlis' net worth.
How do I contact V. Bryan Lawlis?
The corporate mailing address for Dr. Lawlis and other Geron executives is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. Geron can also be reached via phone at (650) 473-7700 and via email at investor@geron.com. Learn More on V. Bryan Lawlis' contact information.
Has V. Bryan Lawlis been buying or selling shares of Geron?
V. Bryan Lawlis has not been actively trading shares of Geron during the last ninety days. Most recently, V Bryan Lawlis sold 35,000 shares of the business's stock in a transaction on Thursday, May 11th. The shares were sold at an average price of $3.00, for a transaction totalling $105,000.00. Learn More on V. Bryan Lawlis' trading history.
Who are Geron's active insiders?
Geron's insider roster includes Faye Feller (Executive Vice President, Chief Medical Officer), Andrew Grethlein (xecutive Vice President, Chief Operating Officer), V. Lawlis (Director), Susan Molineaux (Director), Elizabeth O'Farrell (Director), Scott Samuels (Executive Vice President, Chief Legal Officer and Secretary), John Scarlett (CEO), and Robert Spiegel (Director). Learn More on Geron's active insiders.
Are insiders buying or selling shares of Geron?
During the last twelve months, Geron insiders bought shares 2 times. They purchased a total of 27,500 shares worth more than $46,150.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 1,562,248 shares worth more than $6,808,003.88. The most recent insider tranaction occured on February, 27th when EVP Scott Alan Samuels bought 15,000 shares worth more than $24,150.00. Insiders at Geron own 3.1% of the company.
Learn More about insider trades at Geron. Information on this page was last updated on 2/27/2025.
